Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 4:12:e86015.
doi: 10.7554/eLife.86015.

Viral persistence, reactivation, and mechanisms of long COVID

Benjamin Chen  1 , Boris Julg  2 , Sindhu Mohandas  3 , Steven B Bradfute  4 ; RECOVER Mechanistic Pathways Task Force
Collaborators, Affiliations
Review

Viral persistence, reactivation, and mechanisms of long COVID

Benjamin Chen et al. Elife. .

Abstract

The COVID-19 global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has infected hundreds of millions of individuals. Following COVID-19 infection, a subset can develop a wide range of chronic symptoms affecting diverse organ systems referred to as post-acute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. A National Institutes of Health-sponsored initiative, RECOVER: Researching COVID to Enhance Recovery, has sought to understand the basis of long COVID in a large cohort. Given the range of symptoms that occur in long COVID, the mechanisms that may underlie these diverse symptoms may also be diverse. In this review, we focus on the emerging literature supporting the role(s) that viral persistence or reactivation of viruses may play in PASC. Persistence of SARS-CoV-2 RNA or antigens is reported in some organs, yet the mechanism by which they do so and how they may be associated with pathogenic immune responses is unclear. Understanding the mechanisms of persistence of RNA, antigen or other reactivated viruses and how they may relate to specific inflammatory responses that drive symptoms of PASC may provide a rationale for treatment.

Keywords: PASC; Reactivation; SARS-CoV-2; epidemiology; global health; immunology; inflammation; long COVID; viral persistence.

PubMed Disclaimer

Conflict of interest statement

BC, BJ, SM, SB No competing interests declared

Figures

Figure 1.
Figure 1.. Summary of potential viral, immune, and tissue roles in post-acute sequelae of SARS CoV-2 infection (PASC).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nature Reviews. Immunology. 2020;20:397–398. doi: 10.1038/s41577-020-0346-x. - DOI - PMC - PubMed
    1. Aguilar-Bretones M, Westerhuis BM, Raadsen MP, de Bruin E, Chandler FD, Okba NM, Haagmans BL, Langerak T, Endeman H, van den Akker JP, Gommers DA, van Gorp EC, GeurtsvanKessel CH, de Vries RD, Fouchier RA, Rockx BH, Koopmans MP, van Nierop GP. Seasonal Coronavirus-specific B cells with limited SARS-Cov-2 cross-reactivity dominate the IgG response in severe COVID-19. The Journal of Clinical Investigation. 2021;131:e150613. doi: 10.1172/JCI150613. - DOI - PMC - PubMed
    1. Anand SP, Prévost J, Nayrac M, Beaudoin-Bussières G, Benlarbi M, Gasser R, Brassard N, Laumaea A, Gong SY, Bourassa C, Brunet-Ratnasingham E, Medjahed H, Gendron-Lepage G, Goyette G, Gokool L, Morrisseau C, Bégin P, Martel-Laferrière V, Tremblay C, Richard J, Bazin R, Duerr R, Kaufmann DE, Finzi A. Longitudinal analysis of humoral immunity against SARS-Cov-2 spike in Convalescent individuals up to 8 months post-symptom onset. Cell Reports. Medicine. 2021;2:100290. doi: 10.1016/j.xcrm.2021.100290. - DOI - PMC - PubMed
    1. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, Gouma S, McAllister CM, Christensen SR, Weaver J, Hicks P, Manzoni TB, Oniyide O, Ramage H, Mathew D, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, D’Andrea K, Kuthuru O, Dougherty J, Pattekar A, Kim J, Han N, Apostolidis SA, Huang AC, Vella LA, Kuri-Cervantes L, Pampena MB, Betts MR, Wherry EJ, Meyer NJ, Cherry S, Bates P, Rader DJ, Hensley SE, UPenn COVID Processing Unit Seasonal human Coronavirus antibodies are boosted upon SARS-Cov-2 infection but not associated with protection. Cell. 2021;184:1858–1864. doi: 10.1016/j.cell.2021.02.010. - DOI - PMC - PubMed
    1. Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, Lanzavecchia A, Corti D, Virgin HW. A perspective on potential antibody-dependent enhancement of SARS-Cov-2. Nature. 2020;584:353–363. doi: 10.1038/s41586-020-2538-8. - DOI - PubMed

Publication types